Pharma company Roche has been awarded World Health Organization (WHO) prequalification for its cobas HPV test. This move increases access to critical cervical cancer screening tools in low and lower-middle income countries, where the disease is most prevalent and deadly. Each year, over 600,000 women around the world are diagnosed with cervical cancer, with more than 340,000 succumbing to the preventable disease,…
Novartis has unveiled significant findings from the Phase III NATALEE trial, demonstrating that Kisqali (ribociclib) can effectively reduce the risk of cancer recurrence by 25.2% in patients with early breast cancer. The trial results were presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting and showcased a consistent and clinically meaningful benefit of Kisqali across a broad range of…
Perci Health, an online platform that helps people access multidisciplinary, supportive care throughout their cancer journey, has raised £3.4m in seed funding led by Octopus Ventures. The new funds will allow the company to further invest into its technology roadmap, continue to expand the team and grow access for cancer patients through new partnerships with large employers and insurers. In the last few…
During its annual health event, The Check Up, Google unveiled several new healthcare partnerships with a focus on artificial intelligence. In recent years, the tech giant has invested significant attention and resources into healthcare in a bid to further integrate itself into the burgeoning industry. One highlight of the event was Google’s announcement that its Med-PaLM 2 language model can now provide…
Ahead of International Women’s Day, new preliminary findings from the Apple Women’s Health Study underscore the importance of paying attention to the menstrual cycle and its connection to overall health. Many physicians consider periods a vital sign, yet this area of health is notably under-researched. The Apple Women’s Health Study is a first-of-its-kind research study conducted with the Harvard T.H. Chan School of Public…
MyOme has announced the publication of a validation study for its cross-ancestry, integrated risk score in JCO Precision Oncology. The study tested the association between the caIRS and breast cancer in retrospective data from two validation cohorts with longitudinal follow-up amounting to over 130,000 women and demonstrated that MyOme’s cross-ancestry, integrated risk score significantly improved breast cancer risk prediction over the common…
The following guest post was written by Rosy Founder & CEO Lyndsey Harper, MD. Dr. Harper created the first-of-its-kind platform out of frustration, when she couldn’t find a modern and accessible resource to help her patients. Rosy is a resource to connect the 84 million women in the US with sexual problems with hope, community, and research-backed solutions to improve their lives.…
Qvin, the biotech company that developed a healthcare solution that collects menstrual blood to test for HR-HPV and other critical healthcare information, has received FDA approval in Thailand for its Q-Pad technology. This approval will make it possible for Thailand residents who menstruate to test for HR-HPV with Qvin’s Q-Pad this year. Thailand has a population of 30 million women ages 15 years and older who are at…
